(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 28.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 105.75%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Tg Therapeutics's revenue in 2025 is $531,898,000.On average, 10 Wall Street analysts forecast TGTX's revenue for 2025 to be $95,225,506,304, with the lowest TGTX revenue forecast at $90,673,872,844, and the highest TGTX revenue forecast at $98,684,874,742. On average, 10 Wall Street analysts forecast TGTX's revenue for 2026 to be $141,932,536,789, with the lowest TGTX revenue forecast at $130,224,027,277, and the highest TGTX revenue forecast at $154,531,686,820.
In 2027, TGTX is forecast to generate $178,128,104,022 in revenue, with the lowest revenue forecast at $147,944,757,198 and the highest revenue forecast at $210,673,791,477.